IGM Biosciences Inc . (NASDAQ:IGMS) stock has tumbled to a 52-week low, reaching a price level of just $1.59 USD. With a ...

Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected]?or ...

IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock ...

IGM Biosciences Inc (IGMS) stock saw a modest uptick, ending the day at $2 which represents a slight increase of $0.29 or 16.96% from the prior close of $1.71. The stock opened at $1.75 and touched a ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector perform rating in a report released on Friday, MarketBeat.com reports. The ...

IGMS stock opened at $2.09 on Friday. The stock has a 50-day simple moving average of $8.94 and a two-hundred day simple moving average of $10.92. IGM Biosciences has a twelve month low of $1.87 ...

Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold. Analyst Price Forecast Suggests 858.18% Upside As of December 23, 2024, ...

https://www.tipranks.com/news/the-fly/irhythm-price-target-raised-to-125-from-112-at-needham Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval, leading to a greater-than-50% drop in share price. Despite holding substantial liquid assets and a ...